EGFR and neoplasm: For instance, Sorafenib and Erlotinib are multi-target tyrosine kinase inhibitors whose mechanisms of action involve inhibiting signaling pathways such as VEGF and EGFR pathways to block tumor angiogenesis and cell proliferation [56,57].